Onco Sec Medical Incorporated
GPTKB entity
Statements (107)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:acquisition |
gptkb:Tavanta_Therapeutics
TAVO technology |
| gptkbp:allies |
research institutions
|
| gptkbp:business_model |
biopharmaceutical development
biotech development |
| gptkbp:can_lead_to |
gptkb:ONCS-102
TAVO |
| gptkbp:ceo |
gptkb:Daniel_O'_Connor
|
| gptkbp:clinical_trial |
gptkb:United_States
data analysis ongoing Phase 1 combination therapy Phase 2 multiple phases safety and efficacy randomized controlled trials multiple sites Phase 2 trials various sites overall survival advanced cancer patients preliminary results available patient volunteers patients with melanoma Checkpoint Inhibitor Therapy evaluating efficacy |
| gptkbp:collaborates_with |
academic institutions
|
| gptkbp:collaboration |
gptkb:University_of_California,_San_Diego
biotech firms |
| gptkbp:collaborations |
gptkb:academic_research
pharmaceutical companies with academic institutions with pharmaceutical companies immunotherapy research |
| gptkbp:develops |
Immuno Pulse
|
| gptkbp:eligibility |
clinical studies
|
| gptkbp:financial_reports |
quarterly earnings
|
| gptkbp:focus |
cancer immunotherapy
|
| gptkbp:focuses_on |
cancer immunotherapy
|
| gptkbp:founded |
gptkb:2012
|
| gptkbp:funding |
gptkb:venture_capital
grants and investments secured funding |
| gptkbp:grants |
awarded grants
|
| gptkbp:has_advisory_board |
experts in oncology
|
| gptkbp:head_of_state |
strategic initiatives
strategic growth |
| gptkbp:headcount |
approximately 30
|
| gptkbp:headquarters |
gptkb:San_Diego,_California
|
| gptkbp:healthcare |
not yet approved
|
| https://www.w3.org/2000/01/rdf-schema#label |
Onco Sec Medical Incorporated
|
| gptkbp:innovation |
focused on cancer therapy
|
| gptkbp:instruction_set |
future therapies
therapeutic candidates |
| gptkbp:invention |
multiple patents filed
electroporation technology |
| gptkbp:investment |
gptkb:public_company
available online annual meetings institutional investors financial performance publicly traded quarterly reports engaged with shareholders |
| gptkbp:investment_focus |
gptkb:cancer_treatment
solid tumors |
| gptkbp:investment_strategy |
market trends
|
| gptkbp:investor_meetings |
regularly scheduled
|
| gptkbp:is_a_platform_for |
electroporation
|
| gptkbp:is_tested_for |
predictive indicators
|
| gptkbp:market |
oncology sector
|
| gptkbp:market_position |
oncology market
|
| gptkbp:marketing_strategy |
clinical development
focused on oncology |
| gptkbp:partnership |
gptkb:Merck_&_Co.
clinical research organizations |
| gptkbp:partnerships |
biopharmaceutical companies
with research institutions |
| gptkbp:pipeline_products |
in development
|
| gptkbp:product |
ongoing research
therapeutic innovations TAVO Immuno Pulse |
| gptkbp:publications |
peer-reviewed journals
published research articles |
| gptkbp:regulatory_compliance |
gptkb:FDA
under investigation clinical trial applications |
| gptkbp:related_products |
IND application
|
| gptkbp:research_areas |
tumor microenvironment
solid tumors immune response enhancement |
| gptkbp:research_focus |
novel therapies
intratumoral delivery |
| gptkbp:revenue |
not publicly disclosed
|
| gptkbp:scientific_advisory_board_members |
leading oncologists
|
| gptkbp:stock_symbol |
ONCS
|
| gptkbp:target_market |
gptkb:Oncology
|
| gptkbp:team |
experienced professionals
experienced executives |
| gptkbp:technology |
TAVO
|
| gptkbp:therapeutic_indications |
various cancers
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:treatment |
patient responses
|
| gptkbp:website |
www.oncosec.com
|